The cytokine network in acute myeloid leukemia.
| Autor: | Luciano M; Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.; Cancer Cluster Salzburg, Salzburg, Austria., Krenn PW; Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.; Cancer Cluster Salzburg, Salzburg, Austria., Horejs-Hoeck J; Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.; Cancer Cluster Salzburg, Salzburg, Austria. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in immunology [Front Immunol] 2022 Sep 28; Vol. 13, pp. 1000996. Date of Electronic Publication: 2022 Sep 28 (Print Publication: 2022). |
| DOI: | 10.3389/fimmu.2022.1000996 |
| Abstrakt: | Acute myeloid leukemia (AML) is a highly heterogeneous malignancy of the blood and bone marrow, characterized by clonal expansion of myeloid stem and progenitor cells and rapid disease progression. Chemotherapy has been the first-line treatment for AML for more than 30 years. Application of recent high-throughput next-generation sequencing technologies has revealed significant molecular heterogeneity to AML, which in turn has motivated efforts to develop new, targeted therapies. However, due to the high complexity of this disease, including multiple driver mutations and the coexistence of multiple competing tumorigenic clones, the successful incorporation of these new agents into clinical practice remains challenging. These continuing difficulties call for the identification of innovative therapeutic approaches that are effective for a larger cohort of AML patients. Recent studies suggest that chronic immune stimulation and aberrant cytokine signaling act as triggers for AML initiation and progression, facets of the disease which might be exploited as promising targets in AML treatment. However, despite the greater appreciation of cytokine profiles in AML, the exact functions of cytokines in AML pathogenesis are not fully understood. Therefore, unravelling the molecular basis of the complex cytokine networks in AML is a prerequisite to develop new therapeutic alternatives based on targeting cytokines and their receptors. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Luciano, Krenn and Horejs-Hoeck.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|